Congress Asset Management Co. Acquires 13,009 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Congress Asset Management Co. grew its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 722,325 shares of the medical instruments supplier's stock after buying an additional 13,009 shares during the quarter. Congress Asset Management Co. owned 3.21% of LeMaitre Vascular worth $66,555,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in LMAT. NBC Securities Inc. raised its position in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 183 shares in the last quarter. KBC Group NV raised its position in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after buying an additional 410 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at approximately $150,000. SG Americas Securities LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at approximately $158,000. Finally, Advisors Asset Management Inc. raised its position in shares of LeMaitre Vascular by 180.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier's stock valued at $172,000 after buying an additional 1,191 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 2.4 %

LMAT traded up $2.41 during trading on Wednesday, reaching $103.15. 200,135 shares of the company's stock were exchanged, compared to its average volume of 157,800. LeMaitre Vascular, Inc. has a one year low of $59.87 and a one year high of $109.58. The stock has a market capitalization of $2.32 billion, a PE ratio of 56.37, a price-to-earnings-growth ratio of 2.17 and a beta of 0.96. The firm has a fifty day moving average price of $95.97 and a two-hundred day moving average price of $93.74.

Analysts Set New Price Targets

LMAT has been the subject of several analyst reports. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Oppenheimer reiterated an "outperform" rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $94.63.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.